Y. Ben-neriah, G. Daley, and A. Mes-masson, The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene, Science, vol.233, issue.4760, pp.212-216, 1986.
DOI : 10.1126/science.3460176

E. Shtivelman, B. Lifshitz, and R. Gale, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia, Nature, vol.74, issue.6020, pp.550-554, 1985.
DOI : 10.1038/315550a0

W. Smit, M. Rijnbeek, and C. Van-bergen, T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation, Proceedings of the National Academy of Sciences, vol.95, issue.17, pp.10152-10159, 1998.
DOI : 10.1073/pnas.95.17.10152

W. Drobyski, C. Keever, and M. Roth, Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose, Blood, vol.82, pp.2310-2318, 1993.

H. Kolb, J. Mittermü-ller, and C. Clemm, Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients, Blood, vol.76, pp.2462-2467, 1990.

H. Kolb, A. Schattenberg, and J. Goldman, Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients, Blood, vol.86, pp.2041-50, 1995.

M. Aguet, M. Grobke, and P. Dreiding, Various human interferon a subclasses cross-react with common receptors: Their binding affinities correlate with their specific biological activities, Virology, vol.132, issue.1, pp.211-217, 1984.
DOI : 10.1016/0042-6822(84)90105-3

G. Merlin, E. Falcoff, and M. Aguet, 125I-labelled Human Interferons Alpha, Beta and Gamma: Comparative Receptor-binding Data, Journal of General Virology, vol.66, issue.5, pp.1149-52, 1985.
DOI : 10.1099/0022-1317-66-5-1149

L. Pfeffer, C. Dinarello, and R. Herberman, Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons, Cancer Res, vol.58, pp.2489-99, 1998.

J. Gutterman, Cytokine therapeutics: lessons from interferon alpha., Proceedings of the National Academy of Sciences, vol.91, issue.4, pp.1198-205, 1994.
DOI : 10.1073/pnas.91.4.1198
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43124

H. Harada, T. Taniguchi, and N. Tanaka, The role of interferon regulatory factors in the interferon system and cell growth control, Biochimie, vol.80, issue.8-9, pp.641-50, 1998.
DOI : 10.1016/S0300-9084(99)80017-0

F. Siegal, N. Kadowaki, and M. Shodell, The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood, Science, vol.284, issue.5421, pp.1835-1842, 1999.
DOI : 10.1126/science.284.5421.1835

T. Nagamura-inoue, T. Tamura, and K. Ozato, Transcription Factors that Regulate Growth and Differentiation of Myeloid Cells, International Reviews of Immunology, vol.12, issue.1, pp.83-105, 2001.
DOI : 10.1038/35901

N. Nelson, Y. Kanno, and C. Hong, Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation, J Immunol, vol.156, pp.3711-3731, 1996.

P. Driggers, D. Ennist, and S. Gleason, An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes., Proceedings of the National Academy of Sciences, vol.87, issue.10, pp.3743-3750, 1990.
DOI : 10.1073/pnas.87.10.3743

A. Weisz, P. Marx, and R. Sharf, Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes, J Biol Chem, vol.267, pp.25589-96, 1992.

M. Schmidt, S. Nagel, and J. Proba, Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukaemias, Blood, vol.91, pp.22-31, 1998.

M. Schmidt, A. Hochhaus, and A. Nitsche, Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha, Blood, vol.97, issue.11, pp.3648-50, 2001.
DOI : 10.1182/blood.V97.11.3648

S. Hao and R. Ren, Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder, Molecular and Cellular Biology, vol.20, issue.4, pp.1149-61, 2000.
DOI : 10.1128/MCB.20.4.1149-1161.2000

T. Tamura, H. Kong, and C. Tunyaplin, ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells, Blood, vol.102, issue.13, pp.4547-54, 2003.
DOI : 10.1182/blood-2003-01-0291

T. Holtschke, J. Lohler, and Y. Kanno, Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene, Cell, vol.87, issue.2, pp.307-324, 1996.
DOI : 10.1016/S0092-8674(00)81348-3

M. Deng and G. Daley, Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia, Blood, vol.97, issue.11, pp.3491-3498, 2001.
DOI : 10.1182/blood.V97.11.3491

C. Asselin-paturel, A. Boonstra, and M. Dalod, Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology, Nature Immunology, vol.250, issue.12, pp.1144-50, 2001.
DOI : 10.1006/clim.2000.4858

G. Schiavoni, F. Mattei, and P. Sestili, Dendritic Cells, The Journal of Experimental Medicine, vol.162, issue.11, pp.1415-1440, 2002.
DOI : 10.4049/jimmunol.166.9.5448

S. Sacchi, H. Kantarjian, and S. O-'brien, Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia., Journal of Clinical Oncology, vol.13, issue.9, pp.2401-2408, 1995.
DOI : 10.1200/JCO.1995.13.9.2401

R. Paquette, N. Hsu, and J. Said, Interferon-?? induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo, Leukemia, vol.16, issue.8, pp.1484-1493, 2002.
DOI : 10.1038/sj.leu.2402602

T. Oka, K. Sastry, and P. Nehete, Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon, Leukemia, vol.12, issue.2, pp.155-63, 1998.
DOI : 10.1038/sj.leu.2400919

T. Holyoake, X. Jiang, and C. Eaves, Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukaemia, Blood, vol.94, pp.2056-64, 1999.

S. Graham, H. Jorgensen, and E. Allan, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro, Blood, vol.99, issue.1, pp.319-344, 2002.
DOI : 10.1182/blood.V99.1.319

M. Copland, A. Hamilton, and L. Elrick, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction, Blood, vol.107, issue.11, pp.4532-4541, 2006.
DOI : 10.1182/blood-2005-07-2947

X. Jiang, Y. Zhao, and C. Smith, Chronic myeloid leukaemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies, Leukemia, vol.21, pp.926-961, 2007.

M. Essers, S. Offner, and W. Blanco-bose, IFN?? activates dormant haematopoietic stem cells in vivo, Nature, vol.6, issue.7240, pp.904-912, 2009.
DOI : 10.1038/nature07815

T. Sato, N. Onai, and H. Yoshihara, Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon???dependent exhaustion, Nature Medicine, vol.1106, issue.6, pp.696-700, 2009.
DOI : 10.1038/nm.1973

M. Chawla-sarkar, D. Lindner, and Y. Liu, Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis, Apoptosis, vol.8, issue.3, pp.237-286, 2003.
DOI : 10.1023/A:1023668705040

S. Der, A. Zhou, and B. Williams, Identification of genes differentially regulated by interferon ??, ??, or ?? using oligonucleotide arrays, Proceedings of the National Academy of Sciences, vol.95, issue.26, pp.15623-15631, 1998.
DOI : 10.1073/pnas.95.26.15623

C. Selleri, T. Sato, D. Vecchio, and L. , Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia, Blood, vol.89, pp.957-64, 1997.

C. Peschel, W. Aulitzky, and C. Huber, Influence of Interferon-?? on Cytokine Expression by the Bone Marrow Microenvironment???Impact on Treatment of Myeloproliferative Disorders, Leukemia & Lymphoma, vol.77, issue.1, pp.129-163, 1996.
DOI : 10.1084/jem.165.3.914

R. Bhatia and C. Verfaillie, The Effect of Interferon-?? on Beta-1 Integrin Mediated Adhesion and Growth Regulation in Chronic Myelogenous Leukemia, Leukemia & Lymphoma, vol.269, issue.21, pp.241-54, 1998.
DOI : 10.1083/jcb.123.6.1889

C. Dowding, M. Gordon, and A. Guo, in CML, Leukemia & Lymphoma, vol.265, issue.sup1, pp.185-91, 1993.
DOI : 10.1083/jcb.114.1.143

M. Talpaz, H. Kantarjian, and K. Mccredie, Clinical investigation of human alpha interferon in chronic myelogenous leukemia, Blood, vol.69, pp.1280-1288, 1987.

M. Kantarjian, O. Brien, S. Anderlini, and P. , Treatment of chronic myelogenous leukemia: current status and investigational options, Blood, vol.87, pp.3069-81, 1996.

N. Niederle, O. Kloke, and U. Wandl, Long-Term Treatment of Chronic Myelogenous Leukemia with Different Interferons: Results from Three Studies, Leukemia & Lymphoma, vol.76, issue.1-2, pp.111-120, 1993.
DOI : 10.1016/0305-7372(90)90019-C

H. Ozer, S. George, and C. Schiffer, Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583, Blood, vol.82, pp.2975-84, 1993.

G. Alimena, E. Morra, and . Lazzarino, Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration, Blood, vol.72, pp.642-649, 1989.

M. Freund, V. Wussow, P. Diedrich, and H. , Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies, British Journal of Haematology, vol.104, issue.3, pp.350-356, 1989.
DOI : 10.1007/BF00207259

J. Schofield, W. Robinson, and J. Murphy, Low Doses of Interferon-?? Are as Effective as Higher Doses in Inducing Remissions and Prolonging Survival in Chronic Myeloid Leukemia, Annals of Internal Medicine, vol.121, issue.10, pp.736-780, 1994.
DOI : 10.7326/0003-4819-121-10-199411150-00002

R. Hehlmann, H. Heimpel, and J. Hasford, Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia (CML), Blood, vol.84, pp.4064-77, 1994.

N. Allan, S. Richards, and P. Shepherd, UK Medical Research Council randomised, multicentre trial of interferon-??n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response, The Lancet, vol.345, issue.8962, pp.1392-1399, 1995.
DOI : 10.1016/S0140-6736(95)92596-1

K. Ohnishi, R. Ohno, and M. Tomonaga, A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase, Blood, vol.86, pp.906-922, 1995.

R. Hehlmann, U. Berger, and M. Pfirrmann, Randomized comparison of interferon ?? and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon ?? and hydroxyurea, Leukemia, vol.17, issue.8, pp.1529-1566, 2003.
DOI : 10.1038/sj.leu.2403006

J. Sokal, J. Gockerman, and S. Bibner, Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia, Leukemia Research, vol.12, issue.6, pp.453-461, 1988.
DOI : 10.1016/0145-2126(88)90110-5

F. Guilhot, B. Dreyfus, and A. Brizard, Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside, Leukemia & Lymphoma, vol.73, issue.1, pp.49-55, 1991.
DOI : 10.1016/S0140-6736(89)92733-5

H. Kantarjian, M. Keating, and E. Estey, Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine., Journal of Clinical Oncology, vol.10, issue.5, pp.772-780, 1992.
DOI : 10.1200/JCO.1992.10.5.772

H. Kantarjian, O. Brien, S. Beran, and M. , Interferon alpha (IFN-A) and low-dose cytosine arabinoside (Ara-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML), Blood, vol.86, 1995.

F. Guilhot, C. Chastang, and M. Michallet, Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia, New England Journal of Medicine, vol.337, issue.4, pp.223-232, 1997.
DOI : 10.1056/NEJM199707243370402

F. Guilhot, A. Guerci, and F. Maloisel, Follow-up of 1047 patients with chronic myelogenous leukemia treated with interferon or interferon with cytarabine, Blood, vol.90, 1997.

M. Baccarani, G. Rosti, D. Vivo, and A. , A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia, Blood, vol.99, issue.5, pp.1527-1562, 2002.
DOI : 10.1182/blood.V99.5.1527

T. Kü-hr, S. Burgstaller, and U. Apfelbeck, A randomized study comparing interferon (IFN??) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML), Leukemia Research, vol.27, issue.5, pp.405-416, 2003.
DOI : 10.1016/S0145-2126(02)00223-0

F. Maloisel, A. Guerci, and D. Guyotat, Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon ??-2b for the treatment of chronic myelogenous leukemia patients in chronic phase, Leukemia, vol.16, issue.4, pp.573-80, 2002.
DOI : 10.1038/sj.leu.2402433

G. Rosti, F. Bonifazi, and E. Trabacchi, A phase II study of ??-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia, Leukemia, vol.17, issue.3, pp.554-563, 2003.
DOI : 10.1038/sj.leu.2402850

F. Cervantes, A. Sureda, and J. Hernandez-boluda, Interferona plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon, Haematologica, vol.86, pp.1281-1287, 2001.

T. Kü-hr, W. Eisterer, and U. Apfelbeck, Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01):, Leukemia Research, vol.24, issue.7, pp.583-590, 2000.
DOI : 10.1016/S0145-2126(00)00036-9

A. Hochhaus, S. Kreil, and A. Corbin, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy, Leukemia, vol.16, issue.11, pp.2190-2196, 2002.
DOI : 10.1038/sj.leu.2402741

J. Lucy, H. Jorgensen, and J. Mountford, Punish the parent not the progeny, Blood, vol.105, pp.1862-1868, 2005.

J. Lipton, N. Khoroshko, and A. Golenkov, interferon ??-2a (Roferon??-A) in patients with treatment-na??ve, chronic-phase chronic myelogenous leukemia, Leukemia & Lymphoma, vol.49, issue.1, pp.497-505, 2007.
DOI : 10.1002/cncr.11831

M. Michallet, F. Maloisel, and M. Delain, Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study, Leukemia, vol.18, issue.2, pp.309-324, 2004.
DOI : 10.1038/sj.leu.2403217

M. Baccarani, G. Martinelli, and G. Rosti, Imatinib and pegylated human recombinant interferon-??2b in early chronic-phase chronic myeloid leukemia, Blood, vol.104, issue.13, pp.4245-51, 2004.
DOI : 10.1182/blood-2004-03-0826

F. Palandri, I. Iacobucci, and F. Castagnetti, Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-??: 5-year outcome, Haematologica, vol.93, issue.5, pp.770-774, 2008.
DOI : 10.3324/haematol.12265

O. 'brien, S. Vallance, S. Craddock, and C. , PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myelo?¨dmyelo?¨d leukemia, Blood, vol.98, p.3512, 2001.

R. Hehlmann, S. Sau, and M. Lauseker, Randomized clinical trial for the optimization of Imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV, Haematologica, vol.94, p.478, 2009.

P. Rousselot, C. Preudhomme, and J. Guilhot, Molecular responses of the SPIRIT phase III trial of the French CML group comparing Imatinib 400 mg to higher dose Imatinib or combination with interferon or cytarabine for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients, Haematologica, vol.94, p.1093, 2009.

G. Alimena, M. Breccia, and L. Luciano, Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate, Leukemia Research, vol.32, issue.2, pp.255-61, 2008.
DOI : 10.1016/j.leukres.2007.06.008

F. Bonifazi, A. De-vivo, and G. Rosti, Chronic myeloid leukemia and interferon-alpha : a study of complete cytogenetic responders, Blood, vol.98, issue.10, pp.3074-81, 2001.
DOI : 10.1182/blood.V98.10.3074

S. Parmar, J. Smith, and A. Sassano, Differential regulation of the p70 S6 kinase pathway by interferon a (IFNa) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells, Blood, vol.106, p.7, 2005.